Jim Klostergaard
Overview
Explore the profile of Jim Klostergaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sahin I, Klostergaard J
JCO Oncol Pract
. 2021 Jun;
17(12):723-730.
PMID: 34077235
mutations in colorectal cancer have been studied over the past several decades. V600E mutation, a class I mutation, is the most common oncogenic alteration in colorectal cancer. Until recently, the...
2.
Guler I, Askan G, Klostergaard J, Sahin I
Expert Rev Gastroenterol Hepatol
. 2019 Sep;
13(10):919-931.
PMID: 31475851
: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers with an increasing incidence in the younger patient population. Until the last decade, limited therapeutic options were available for...
3.
Das S, Parga K, Chakraborty I, Tinoco A, Delgado Y, Lopez P, et al.
J Inorg Biochem
. 2018 Jun;
186:176-186.
PMID: 29957454
A water-soluble octanuclear cluster, [Fe], was studied with regard to its properties as a potential contrast enhancing agent in magnetic resonance imaging (MRI) in magnetic fields of 1.3, 7.2 and...
4.
Liang Y, Yu D, Perez-Soler R, Klostergaard J, Zou Y
Oncotarget
. 2018 Jan;
8(65):109596-109608.
PMID: 29312632
Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most...
5.
Sahin I, Klostergaard J
Expert Opin Ther Targets
. 2015 Sep;
19(12):1587-91.
PMID: 26374284
In the treatment of cancers, the dual goals of drug targeting are to deliver therapeutic agents more selectively to tumor tissue and to minimize exposure of normal tissues and organs...
6.
Morlacchi P, Robertson F, Klostergaard J, McMurray J
Future Med Chem
. 2014 Dec;
6(17):1909-26.
PMID: 25495984
Breast cancer is among the most commonly diagnosed cancer types in women worldwide and is the second leading cause of cancer-related disease in the USA. SH2 domains recruit signaling proteins...
7.
McMurray J, Mandal P, Liao W, Klostergaard J, Robertson F
JAKSTAT
. 2013 Sep;
1(4):263-347.
PMID: 24058783
Herein we review our progress on the development of phosphopeptide-based prodrugs targeting the SH2 domain of STAT3 to prevent recruitment to cytokine and growth factor receptors, activation, nuclear translocation and...
8.
Auzenne E, Klostergaard J, Mandal P, Liao W, Lu Z, Gao F, et al.
J Exp Ther Oncol
. 2013 Jan;
10(2):155-62.
PMID: 23350355
Signal transducer and activator of transcription 3 (Stat3) is constitutively activated in a number of human cancers and cancer cell lines. Via its Src homology 2 (SH2) domain, Stat3 is...
9.
Lee S, Ghosh S, Han H, Stone R, Bottsford-Miller J, Shen D, et al.
Clin Cancer Res
. 2012 Jun;
18(15):4114-21.
PMID: 22693353
Purpose: Most primary human ovarian tumors and peritoneal implants, as well as tumor vascular endothelial cells, express the CD44 family of cell surface proteoglycans, the natural ligand for which is...
10.
Klostergaard J, Seeney C
Nanomedicine
. 2012 May;
8 Suppl 1:S37-50.
PMID: 22640907
Nanotechnology holds the promise of novel and more effective treatments for vexing human health issues. Among these are the use of nanoparticle platforms for site-specific delivery of therapeutics to tumors,...